Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leveraging Lilly

Executive Summary

Three years ago, Lilly gambled big on managed care with its acquisition of PCS--and lost. Its new strategy wagers almost as much on research, but this time the bets are hedged. As it aggressively builds infrastructure, it expands its program but limits its own flexibility and diminishes the likelihood that it can exploit all of its programs. Thus it will increasingly outlicense and sell assets it is not exploiting.

Related Content

Lilly & Boehringer: When You Gotta Partner, You Gotta Partner


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts